MAIN CONTENT
The alarm was about independence, not appearance
Ng was diagnosed with type 2 diabetes in June 2023. By December she needed daily insulin injections. Standing 163 centimeters tall, she weighed 69 kilograms that month, having gained weight during perimenopause. A working mother with three children, she had spent much of adult life balancing professional and family demands. The experience will be familiar to people for whom personal health becomes a priority only when ordinary movements begin to feel less secure.
At 52, Ng was troubled by loss of balance and the prospect of falling. That concern makes her story different from the usual celebrity-style before-and-after photographs. The immediate question was not simply whether she could change a clothing size, but whether her body would continue to support independent movement, confidence and participation in everyday life for decades to come.
Where GLP-1 medicines fit into the story
In September 2024, doctors prescribed Ozempic, the semaglutide medicine belonging to the GLP-1 receptor-agonist class. The drug helped suppress her appetite, according to the reported account. This class can improve blood-glucose control and support weight reduction for some patients, but treatment choices depend on individual circumstances, including other health conditions and possible adverse effects.















